Literature DB >> 10764419

Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma?

D Lawson, J M Kirkwood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10764419     DOI： 10.1200/JCO.2000.18.8.1603

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Mucosal melanomas: a case-based review of the literature.

Authors:  Nagashree Seetharamu; Patrick A Ott; Anna C Pavlick
Journal:  Oncologist       Date:  2010-06-22

2.  Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).

Authors:  David H Lawson; Sandra Lee; Fengmin Zhao; Ahmad A Tarhini; Kim A Margolin; Marc S Ernstoff; Michael B Atkins; Gary I Cohen; Theresa L Whiteside; Lisa H Butterfield; John M Kirkwood
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

3.  Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

Authors:  John M Kirkwood; Sandra Lee; Stergios J Moschos; Mark R Albertini; John C Michalak; Cindy Sander; Theresa Whiteside; Lisa H Butterfield; Louis Weiner
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.